<DOC>
	<DOCNO>NCT02780089</DOCNO>
	<brief_summary>This study evaluate different pattern care patient unresectable metastatic melanoma . The dosing , duration , regimen , indication , treatment observe . The survival rate patient also observe .</brief_summary>
	<brief_title>Study Patients With Unresectable And Metastatic Melanoma : The Optimize Study</brief_title>
	<detailed_description>This non-interventional , observational study primary objective ass describe `` real world '' pattern care treatment patient unresectable metastatic melanoma . A sample size 1,600 prospective patient provide sufficient information explore primary objective . There forced number patient enrol specific treatment cohort . Setting control specific treatment enrollment cohort count would invalidate result primary objective study . No primary hypothesis test .</detailed_description>
	<mesh_term>Melanoma</mesh_term>
	<criteria>Prospective cohort patient : Diagnosis date must occur March 24 , 2011 ( date ipilimumab approval US ) Diagnosis stage III ( unresectable ) stage IV melanoma ( include mucosal , uveal acrallentiginous , leptomeningeal disease ) Age ≥ 18 year time entry study Patients must actively receive schedule receive systemic treatment ( line , eg , first , second , third line [ include investigational drug ] ) . For patient initiate new treatment , treatment must start within 28 day sign informed consent . For patient currently receive treatment , patient must enroll within first 21 day start new treatment Retrospective cohort patient : Patients diagnosis confirm unresectable stage III stage IV melanoma ( include mucosal , uveal , acrallentiginous , leptomeningeal disease ) Age ≥ 18 year time unresectable metastatic melanoma diagnosis Initiated therapy unresectable metastatic melanoma within 4 year prior approval ipilimumab ( first immune checkpoint inhibitor therapy approve US ) March 25 , 2007 March 24 , 2011 One year followup data require date therapy initiation , patient pass away within one year followup ; patient still eligible date death collect . 1 . If retrospective patient least one year followup data treat immunooncology , immune checkpoint inhibitor therapy , target therapy , patient analyze separately . Prospective patient : Patients participate clinical study allow enrollment non interventional study clinical study investigational treatment blind Patients start new treatment &gt; 21 day Patients enrol study initiate treatment 28 day Patients current malignancy ( except nonmelanoma skin cancer follow situ cancer : bladder , gastric , colon , endometrial , cervical/dysplasia , melanoma , breast ) require additional systemic therapy</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2016</verification_date>
	<keyword>Metastatic</keyword>
	<keyword>Unresectable</keyword>
</DOC>